In contrast, the anti-growth activity of theasinensin A in combination with nimotuzumab on wild-type EGFR in NCI-H441 cells was much stronger in the wild-type EGFR NSCLC (Figure 2C); therefore, this was selected as a model for investigation of the anti-cancer activity and the underlying mechanisms of the combination with theasinensin A. Next, data from a clonogenic assay further showed that co-treatment with theasinensin A and nimotuzumab induced significant inhibition of NCI-H441 colony formation (Figure 2D,E). Here, EGFR is linked to cancer.